Integrative Guidelines for the Nursing Care of Patients Using Cannabis for Medicinal Purposes
Keywords:
Cannabis for Medical Purposes, Integrative Nursing Guidelines, Medical cannabis knowledgeAbstract
In 2019, Thai federal government has announced the legal use of cannabis in medical care. Since then, the number of cannabis users has been rising up due to its popularity. Resulting in a higher chance of nurses and other healthcare providers in dealing with this group of patients. Presently, medical cannabis knowledge is relatively new and not yet integrated in nursing curriculum and its training course is barely widespread. Moreover, there is no ideal nursing practice guideline announced in Thailand that could develop in other contexts. Hence, it may affect the performance of nurses towards the patients. Culturally sensitive holistic-integrative nursing guidelines for the nursing care of patients using cannabis for medical purposes was therefore developed based on the current best available evidence using the ADAPTE process for guideline adaptation proposed by the ADAPTE collaboration and the drafting guideline was also approved by expert panels and revised as suggested.
This final draft guideline consisted of 4 main categories with 22 sub-sections, including; essential knowledge of medical cannabis in section 1 which was contained with 8 sub-recommendations. Section 2 was provided with the best care for medical cannabis users which was obtained with 6 sub-suggestions. Section 3 was about administration of medicines or medicinal cannabis products which was consisted of 4 sub-advices. Finally, section 4, concerned about ethics in the administration of medicines or medicinal cannabis products which was consisted of 4 sub-suggestions. The developed guidelines would lead to the planning process for trials with the target population in implementation of guidance, results evaluation, effectiveness, flexibility, easiness, feasibility in usage, contributing factors, and obstacles in practicing for further promulgation.
References
ADAPTE II Collaboration. (2010). ADAPTE Resource Toolkit for Guideline Adaptation Version 2.0. [Online] Retrieved November 24, 2019, from http://www.g-i-n.net/ document-store/working-groups-documents/adaptation/adapte-resourcetoolkit-guideline-adaptation-2-0.pdf/view? search term =ADAPTE.
AGREE Next Steps Consortium. (2019). The AGREE II instrument. 2013. Retrieved December 15, 2019 from http://www.agreetrust.org.
Allan, G. M., Ramji, J., Perry, D., Ton, J., Beahm, N. P., Crisp, N., ... & Lindblad, A. J. (2018). Simplified guideline for prescribing medical cannabinoids in primary care. Canadian Family Physician, 64(2), 111-120.
Alsherbiny, M.A., & Li, C.G. (2019). Medicinal Cannabis-Potential drug interactions. Medicines, 6(1), 3.
American Cannabis Nurses Association. (2017). Scope and standards of practice for cannabis nurses. Retrieved November 24, 2019 from https://www.cannabisnurses.org/scope-and-standards-of-practice-for-cannabis-nurses
Department of Health. (2018). Clinical guidance on cannabis for medical use. Retrieved December 15, 2019 from https://health.gov.ie/wp-content/uploads/2018/07/Clinical-guidance-on-canna bisfor-medical-use.pdf
Department of Medical Services. (2021). Guidance on Cannabis for Medical Use. (4th ed.). Retrieved May 21, 2021 from https://mnfda.fda.moph.go.th/narcotic/wp-content/uploads/2021/04/ Guidance -Updated-v-update-V.4260464.pdf
Dizon, J. M., Grimmer, K., Louw, Q., Kredo, T., Young, T., & Machingaidze, S. (2016). South African Guidelines Excellence (SAGE): adopt, adapt, or contextualise? South African Medical Journal, 106(12), 1177-1178.
Dizon, J. M., Machingaidze, S., & Grimmer, K. (2016). To adopt, to adapt, or to contextualise? The big question in clinical practice guideline development. BMC research notes, 9(1), 1-8.
Fervers, B., Burgers, J. S., Voellinger, R., Brouwers, M., Browman, G. P., Graham, I. D., ... & ADAPTE Collaboration. (2011). Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ quality & safety, 20(3), 228-236.
Gonzalez-Suarez, C., Dizon, J. M. R., Grimmer, K., Rafunan, M., Estrada, L. L., & Malleta, A. (2013). Implementation of recommendations from the PARM stroke inpatient rehabilitation guideline: a plan of action. Clinical Audit, 5, 77-89.
Harrison, M. B., Légaré, F., Graham, I. D., & Fervers, B. (2010). Adapting clinical practice guidelines to local context and assessing barriers to their use. Canadian medical association journal, 182(2), E78-E84.
Hillier, S., Grimmer-Somers, K., Merlin, T., Middleton, P., Salisbury, J., Tooher, R., & Weston, A. (2011). FORM: an Australian method for formulating and grading recommendations in evidence-based clinical guidelines. BMC medical research methodology, 11(1), 1-8.
Lucas, C. J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology, 84(11), 2477-2482.
MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European journal of internal medicine, 49, 12-19.
Martínez García, L., Arévalo-Rodríguez, I., Solà, I., Haynes, R. B., Vandvik, P. O., & Alonso-Coello, P. (2012). Strategies for monitoring and updating clinical practice guidelines: a systematic review. Implementation Science, 7(1), 1-10
McGowan, J., Muratov, S., Tsepke, A., Issina, A., Slawecki, E., & Lang, E. S. (2016). Clinical practice guidelines were adapted and implemented meeting country-specific requirements—the example of Kazakhstan. Journal of clinical epidemiology, 69, 8-15.
Ministry of Public Health. (2019). Narcotic Drugs Act No.7, B.E.2562. Retrieved 6 December 2021, from https://mnfda.fda.moph.go.th/narcotic/wp-content/uploads/2021/02/T_0001.pdf
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., ... & Kansagara, D. (2017). The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Annals of internal medicine, 167(5), 319-331.
Queensland Health. (2018). Clinical guidance: for the use of medicinal cannabis products in Queensland. Retrieved December 15, 2019 from https://www.health.qld.gov.au/__data /assets /pdf_ file/ 0023/634163/ med-cannabis-clinicalguide.pdf.
Registered Nurse Association of Ontario. (2017). Engaging Clients Who Use Substances. Retrieved December 15, 2019 from https://rnao.ca/bpg/guidelines/engaging-clients-who-use-substances
Russell, K., Cahill M., Gowen, K., Cronquist, R., Smith, V., Borris-Hale, C., ... , Sutton-Johnson, S., (2018). The NCSBN National Nursing Guidelines for the nursing care of patients using Medical Marijuana. Journal of Nursing Regulation, 9(2), S1 – S60.
Schardt, C., Adams, M. B., Owens, T., Keitz, S., & Fontelo, P. (2007). Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC medical informatics and decision making, 7(1), 1-6.
Schünemann, H. J., Wiercioch, W., Brozek, J., Etxeandia-Ikobaltzeta, I., Mustafa, R. A., Manja, V., ... & Akl, E. A. (2017). GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. Journal of clinical epidemiology, 81, 101-110.
Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S., & Bettiol, S. (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. The Cochrane database of systematic reviews, 12(11).
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., ... & Kleijnen, J. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. The Journal of the American Medical Association, 313(24), 2456-2473.
World Medical Association. (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. The Journal of the American Medical Association, 310(20), 2191-2194.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Princess of Naradhiwas University Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
